STRO - SUTRO BIOPHARMA, INC.
IEX Last Trade
1.925
-2.025 -105.195%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:15:39 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$3.95
-2.03
-51.27%
Fundamental analysis
25%
Profitability
25%
Dept financing
17%
Liquidity
74%
Performance
15%
Performance
5 Days
2.66%
1 Month
-26.05%
3 Months
-41.87%
6 Months
-35.45%
1 Year
-53.94%
2 Year
-71.91%
Key data
Stock price
$1.92
DAY RANGE
$1.84 - $3.95
52 WEEK RANGE
$1.92 - $6.13
52 WEEK CHANGE
-$57.49
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: William J. Newell
Region: US
Website: sutrobio.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sutrobio.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.
Recent news